Histone-deacetylase inhibitors: novel drugs for the treatment of cancer
The DOI matches its Crossref record; 120 of the 121 references it cites were found in a registry or an index.
Abstract
The opposing actions of histone acetyltransferases (HATs) and histone deacetylases (HDACs) allow gene expression to be exquisitely regulated through chromatin remodelling. Aberrant transcription due to altered expression or mutation of genes that encode HATs, HDACs or their binding partners, is a key event in the onset and progression of cancer. HDAC inhibitors can reactivate gene expression and inhibit the growth and survival of tumour cells. The remarkable tumour specificity of these compounds, and their potency in vitro and in vivo, underscore the potential of HDAC inhibitors as exciting new agents for the treatment of cancer.
Overview
Integrity signals
Registry
Cites
Statistics
Verification
Claims the paper makes
Claims other papers make about this one
Each is checked against this paper’s own text: does it say what the citing paper says it does?
In the citing paper
“Acetylation of the core histones of nucleosomes strongly influences gene transcription (Khochbin et al., 2001; Johnstone, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Class I HDACs are ubiquitously expressed and are primarily located in the nucleus, while the class II enzymes can shuttle between the nucleus and cytoplasm and demonstrate tissue-specific expression (Johnstone, 2002; Marks et al., 2001; Vigushin and Coombes, 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
In the citing paper
“Two related classes of eukaryotic zinc-containing HDACs have been recognized based upon sequence similarity: class I (HDAC1, 2, 3, and 8) and class II (HDAC4, 5, 6, 7, 9, and 10) (Johnstone, 2002; Gao et al., 2002).”
From Structural Snapshots of Human HDAC8 Provide Insights into the Class I Histone Deacetylases (2004) · cites this paper as Johnstone, 2002
Citations
Cites
Hanahan, D., & Weinberg, R. A. (2000) · Cell · doi:10.1016/s0092-8674(00)81683-9 · Cited by 29,219
Jenuwein, T., & Allis, C. D. (2001) · Science · doi:10.1126/science.1063127 · Cited by 9,756 · cited 1×
“In general terms, condensed chromatin mediates transcriptional repression, whereas transcriptionally active genes are in areas of open chromati”
BackgroundCrystal structure of the nucleosome core particle at 2.8 Å resolution
Luger, K., Mäder, A. W., Richmond, R. K., Sargent, D. F., & Richmond, T. J. (1997) · Nature · doi:10.1038/38444 · Cited by 9,466
Transcriptional silencing and longevity protein Sir2 is an NAD-dependent histone deacetylase
Imai, S.-I., Armstrong, C. M., Kaeberlein, M., & Guarente, L. (2000) · Nature · doi:10.1038/35001622 · Cited by 3,510 · cited 1×
“pl?locus=sir2">Sir2 , a yeast transcriptional repressor that requires the cofactor NAD + for its deacetylase activit”
BackgroundhSIR2SIRT1 Functions as an NAD-Dependent p53 Deacetylase
Vaziri, H., Dessain, S. K., Eaton, E. N., Imai, S.-I., Frye, R. A., Pandita, T. K., Guarente, L., & Weinberg, R. A. (2001) · Cell · doi:10.1016/s0092-8674(01)00527-x · Cited by 2,659 · cited 3×
“Histone deacetylase inhibitors induce caspase-dependent apoptosis and downregulation of DAXX in acute promyelocytic leukaemia with t(15;17).”
Negative Control of p53 by Sir2α Promotes Cell Survival under Stress
Luo, J., Nikolaev, A. Y., Imai, S.-I., Chen, D., Su, F., Shiloh, A., Guarente, L., & Gu, W. (2001) · Cell · doi:10.1016/s0092-8674(01)00524-4 · Cited by 2,081
Valproic acid defines a novel class of HDAC inhibitors inducing differentiation of transformed cells
Gottlicher, M. (2001) · The EMBO Journal · doi:10.1093/emboj/20.24.6969 · Cited by 1,887 · cited 1×
“asp?DrugCode=1%2D1882&DrugName=VALPROIC+ACID+ORAL&DrugType=1">valproic acid , inhibit HDAC activity and affect the expression of numerous genes with disparate cellular function”
BackgroundHistone deacetylases and cancer: causes and therapies
Marks, P. A., Rifkind, R. A., Richon, V. M., Breslow, R., Miller, T., & Kelly, W. K. (2001) · Nature reviews. Cancer · doi:10.1038/35106079 · Cited by 1,866 · cited 1×
“gov/cancer_information/cancer_type/leukemia/">leukaemias and solid tumours to express differentiated characteristics and stop proliferatin”
BackgroundCameron, E. E., Bachman, K. E., Myöhänen, S., Herman, J. G., & Baylin, S. B. (1999) · Nature Genetics · doi:10.1038/5047 · Cited by 1,857
Acetylation of Histones and Transcription-Related Factors
Sterner, D. E., & Berger, S. L. (2000) · Microbiology and Molecular Biology Reviews · doi:10.1128/mmbr.64.2.435-459.2000 · Cited by 1,780 · cited 5×
“Mechanisms of transcriptional repression by the t(8;21)-, t(12;21)-, and inv(16)-encoded fusion proteins.”
BackgroundInfluential
Research works printed but not linked: 1
- Ruefli, A. A. Suberoylanilide hydroxamic acid (SAHA) overcomes multidrug resistance and induces cell death in P-gp expressing cells. Int. J. Cancer. (in the press).
Cited by
Items 401–500 of 1,001
Kirschbaum, M. H., Foon, K. A., Frankel, P. H., Ruel, C., Pulone, B., Tuscano, J. M., & Newman, E. M. (2013) · Leukemia & lymphoma/Leukemia and lymphoma · doi:10.3109/10428194.2013.877134 · Cited by 74
A Novel Lipid Hydroperoxide-derived Cyclic Covalent Modification to Histone H4
Oe, T., Arora, J. S., Lee, S. H., & Blair, I. A. (2003) · Journal of Biological Chemistry · doi:10.1074/jbc.m308167200 · Cited by 75
Saito, T., Nishida, K., Furumatsu, T., Yoshida, A., Ozawa, M., & Ozaki, T. (2012) · Osteoarthritis and Cartilage · doi:10.1016/j.joca.2012.09.003 · Cited by 82
Mongan, N. P., & Gudas, L. J. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0079 · Cited by 70
“multiple genes silenced during carcinogenesis and thereby restore function of key regulatory pathways, which can inhibit of cancer cell proliferation (55).”
Jeong, M., Ko, H., Jeon, H., Sung, G., Park, S., Jun, W. J., Lee, Y.-H., Lee, J., Lee, S.-W., Yoon, H., et al. (2016) · Oncotarget · doi:10.18632/oncotarget.10790 · Cited by 72
“Clinical trials of HDAC inhibitors for the treatment of both hematopoietic and solid tumors are currently underway [36].”
BackgroundAntitumor activity of the histone deacetylase inhibitor MS‐275 in prostate cancer models
Qian, D. Z., Wei, Y., Wang, X., Kato, Y., Cheng, L., & Пили, Р. (2007) · The Prostate · doi:10.1002/pros.20611 · Cited by 75
“Histone deacetylase (HDAC) inhibitors represent a group of structurally diverse small molecule compounds targeting class I and/or class II histone deacetylases (HDACs) [3,4].”
BackgroundYu, C., Subler, M. A., Rahmani, M., Reese, E., Krystal, G. W., Conrad, D. H., Dent, P., & Grant, S. (2003) · Cancer Biology & Therapy · doi:10.4161/cbt.2.5.454 · Cited by 79
Treatment of chronic kidney diseases with histone deacetylase inhibitors
Liu, N., & Zhuang, S. (2015) · Frontiers in Physiology · doi:10.3389/fphys.2015.00121 · Cited by 73
“Histone deacetylases (HDACs) are known to mediate transcription of genes that trigger immunological responses (Johnstone, 2002; Remiszewski, 2002).”
BackgroundKuo, I., Wu, C.-C., Chang, J.-M., Huang, Y., Lin, C., Yan, J.-J., Sheu, B., Lu, P., Chang, W., Lai, W., et al. (2013) · International Journal of Cancer · doi:10.1002/ijc.28695 · Cited by 69
“For example, previous studies show that SOX6 binds b-catenin and recruits histone deacetylase 1 (HDAC1) to suppress cyclin D1 promoter activity, and the N-terminal 139 amino acids of HDAC1 physically interacts with the HMG box of SOX6.”
BackgroundNewkirk, T. L., Bowers, A. A., & Williams, R. M. (2009) · Natural Product Reports · doi:10.1039/b817886k · Cited by 83
Yu, C., Dasmahapatra, G. P., Dent, P., & Grant, S. (2005) · Leukemia · doi:10.1038/sj.leu.2403868 · Cited by 69
RetractedHsu, C., Khachatryan, L., Younis, N. K., Mustafa, M. A., Ahmad, N., Athab, Z. H., Валерьевна, П. А., Викторовна, К. Е., Mirzaei, R., & Karampoor, S. (2024) · Frontiers in Microbiology · doi:10.3389/fmicb.2024.1456793 · Cited by 83
“…to their function in supplying energy and nutrients to the colonic mucosa, SCFAs play a pivotal role in the maturation of intestinal epithelial cells (IEC), immunological cells, and adipocytes and hence have significant implications for a range of human diseases (Roediger, 1980; Johnstone, 2002).”
BackgroundCzysz, K., Minger, S. L., & Thomas, N. (2015) · PLoS ONE · doi:10.1371/journal.pone.0117689 · Cited by 76
“Although the full role and action of DMSO in cell culture and differentiation remains unknown, it is generally acknowledged that this small molecule may have histone deacetylase inhibitor activity [24] and can convert and/or maintain chromatin in a less compacted state and thus more available for transcription [25].”
BackgroundHistone deacetylase inhibitors induce the degradation of the t(8;21) fusion oncoprotein
Yang, G., Thompson, M. A., Brandt, S. J., & Hiebert, S. W. (2006) · Oncogene · doi:10.1038/sj.onc.1209760 · Cited by 69
“…due solely to inducing the degradation of the fusion protein, as these compounds also trigger death receptormediated apoptosis (Insinga et al., 2005; Sutheesophon et al., 2005) and inhibit chromosomal condensation before mitosis (Blagosklonny et al., 2002; Johnstone, 2002; Piekarz and Bates, 2004).”
BackgroundBaradari, V., Huether, A., Höpfner, M., Schuppan, D., & Scherübl, H. (2006) · Endocrine Related Cancer · doi:10.1677/erc.1.01249 · Cited by 73
“HDAC inhibitors have already been demonstrated to inhibit the growth of several tumors in vitro and in vivo (Kramer et al. 2001, Marks et al. 2001, Vigushin et al. 2001, Johnstone 2002).”
BackgroundInfluentialValproic Acid Inhibits Angiogenesis In Vitro and Glioma Angiogenesis In Vivo in the Brain
Osuka, S., Takano, S., Watanabe, S., Ishikawa, E., Yamamoto, T., & Matsumura, A. (2012) · Neurologia medico-chirurgica · doi:10.2176/nmc.52.186 · Cited by 69
HDAC11 deficiency disrupts oncogene-induced hematopoiesis in myeloproliferative neoplasms
Yue, L., Sharma, V., Horvat, N. P., Akuffo, A. A., Beatty, M. S., Murdun, C., Colin, C., Billington, J. M. R., Goodheart, W. E., Sahakian, E., et al. (2020) · Blood · doi:10.1182/blood.2019895326 · Cited by 67
Qiao, Y.-L., Qian, J., Wang, F.-R., Ma, Z., & Wang, Q.-W. (2013) · Journal of Surgical Research · doi:10.1016/j.jss.2013.08.028 · Cited by 68
Ocker, M., Alajati, A., Ganslmayer, M., Zopf, S., L�ders, M., Neureiter, D., Hahn, E. G., Schuppan, D., & Herold, C. (2005) · Journal of Cancer Research and Clinical Oncology · doi:10.1007/s00432-004-0664-6 · Cited by 75
“Inhibition of HDAC leads to a hyperacetylation of histone residues, leaving the chromatin in an ‘‘open’’ conformation and allowing transcriptional regulators to bind to responsive DNA elements (Johnstone 2002).”
BackgroundA series of novel, potent, and selective histone deacetylase inhibitors
JONES, P. G., Altamura, S., Chakravarty, P. K., Cecchetti, O., Francesco, R. D., Gallinari, P., Ingenito, R., Meinke, P. T., Petrocchi, A., Rowley, M., et al. (2006) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2006.09.002 · Cited by 68
Chen, W., Bao, J., Hu, P., Feng, J., & Wu, L. (2010) · Molecular Biology Reports · doi:10.1007/s11033-010-0055-9 · Cited by 66
Jia, L., Shen, H. C., Wantroba, M., Khalid, O., Liang, G., Wang, Q., Gentzschein, E., Pinski, J. K., Stanczyk, F. Z., Jones, P. A., et al. (2006) · Molecular and Cellular Biology · doi:10.1128/mcb.00581-06 · Cited by 66
“Acetylation, catalyzed by histone acetyltransferases such as p300/CBP, is reversed by the activity of histone deacetylases, which mediate transcriptional repression (21).”
BackgroundRenzo, F. D., Cappelletti, G., Broccia, M. L., Giavini, E., & Menegola, E. (2007) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2007.01.001 · Cited by 65
“Their activity is opposite that of histone acetyltransferase enzymes (HATs): HATs function as transcriptional co-activators by acetylating histone lysine-NH2 groups, while HDACs deacetylate lysine residues on histone tails and induce transcriptional repression through chromatine condensation (Johnstone, 2002).”
BackgroundNew method to detect histone acetylation levels by flow cytometry
Ronzoni, S., Faretta, M., Ballarini, M., Pelicci, P., & Minucci, S. (2005) · Cytometry Part A · doi:10.1002/cyto.a.20151 · Cited by 66
“In fact, clinical trials have started to evaluate the efficacy of HDACi in nonleukemic patients (12).”
BackgroundCrabb, S. J., Howell, M., Rogers, H., Ishfaq, M., Yurek‐George, A., Carey, K. L., Pickering, B. M., East, P., Mitter, R., Maeda, S., et al. (2008) · Biochemical Pharmacology · doi:10.1016/j.bcp.2008.06.004 · Cited by 71
“Histone acetylation plays a major role in controlling gene expression, by modulating chromatin packaging in combination with other post-translational modifications (such as methylation and phosphorylation) creating a ‘‘histone code’’ which is read by transcriptional regulators that recognise these marks [1,2].”
BackgroundBjörkman, M. L., Iljin, K., Halonen, P., Sara, H., Kaivanto, E., Nees, M., & Kallioniemi, O. (2008) · International Journal of Cancer · doi:10.1002/ijc.23885 · Cited by 73
The role of epigenetics in environmental and occupational carcinogenesis
Ziech, D., Franco, R., Pappa, A., Malamou‐Mitsi, V., Georgakila, S., Georgakilas, A. G., & Panayiotidis, M. I. (2010) · Chemico-Biological Interactions · doi:10.1016/j.cbi.2010.06.012 · Cited by 72
Rokhlin, O. W., Glover, R. B., Guseva, N. V., Taghiyev, A. F., Kohlgraf, K. G., & Cohen, M. B. (2006) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-05-0085 · Cited by 66
“apoptosis in several cancer cell lines (1).”
BackgroundInfluentialHaendler (2009) · International Journal of Oncology · doi:10.3892/ijo_00000406 · Cited by 66
Differential protein acetylation induced by novel histone deacetylase inhibitors
Glaser, K. B., Li, J., Pease, L. J., Staver, M. J., Marcotte, P. A., Guo, J., Frey, R. R., Garland, R. B., Heyman, H. R., Wada, C. K., et al. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.10.082 · Cited by 71
Butler, L. M., Liapis, V., Bouralexis, S., Welldon, K. J., Hay, S. J., Thai, L. M., Labrinidis, A., Tilley, W. D., Findlay, D. M., & Evdokiou, A. (2006) · International Journal of Cancer · doi:10.1002/ijc.21939 · Cited by 75
“Histone deacetylase (HDAC) inhibitors are a series of agents that inhibit the growth of a range of transformed cells in vitro and in vivo, and are currently in Phase I/II clinical trials for treatment of hematological and solid tumor malignancies, with demonstrated clinical efficacy.(8,9) In vivo studies of HDAC inhib…”
BackgroundLian, B., Chen, X., & Shen, K. (2023) · Frontiers in Immunology · doi:10.3389/fimmu.2023.1164514 · Cited by 75
Non-Peptide Macrocyclic Histone Deacetylase Inhibitors Derived from Tricyclic Ketolide Skeleton
Mwakwari, S. C., Guerrant, W., Patil, V., Khan, S. I., Tekwani, B. L., Gurard‐Levin, Z. A., Mrksich, M., & Oyelere, A. K. (2010) · Journal of Medicinal Chemistry · doi:10.1021/jm100507q · Cited by 68
Estella, C., Herrer, I., Atkinson, S. P., Quiñonero, A., Martínez, S., Pellicer, A., & Simón, C. (2012) · PLoS ONE · doi:10.1371/journal.pone.0030508 · Cited by 68
“HDAC inhibitors are currently being developed as cancer therapeutics, mainly because of their ability to inhibit cancer cell growth in vitro and in vivo, to induce apoptosis, and to enhance cell differentiation [39,40].”
BackgroundDasmahapatra, G. P., Yerram, N. K., Dai, Y., Dent, P., & Grant, S. (2007) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-0835 · Cited by 66
RetractedLi, J., Bonifati, S., Hristov, G., Marttila, T., Valmary‐Degano, S., Stanzel, S. F., Schnölzer, M., Mougin, C., Aprahamian, M., Grekova, S. P., et al. (2013) · EMBO Molecular Medicine · doi:10.1002/emmm.201302796 · Cited by 78
“Gene expression profiling studies have indicated that HDACI treatment dysregulates the transcription of about 10% of all cellular genes (Johnstone, 2002).”
Anti‐cancer potential of selenium‐ and tellurium‐containing species: opportunities abound!
Seng, H., & Tiekink, E. R. T. (2012) · Applied Organometallic Chemistry · doi:10.1002/aoc.2928 · Cited by 70
Han, R., Sun, Q., Wu, J., Zheng, P., & Zhao, G. (2016) · Cellular Physiology and Biochemistry · doi:10.1159/000447889 · Cited by 65
RetractedEpigenetics: a link between addiction and social environment
Ajonijebu, D. C., Abboussi, O., Russell, V. A., Mabandla, M. V., & Daniels, W. M. U. (2017) · Cellular and Molecular Life Sciences · doi:10.1007/s00018-017-2493-1 · Cited by 68
“HDAC inhibitors have been considered for many years as potent anticancer agents [111, 112].”
BackgroundHistone deacetylase inhibitors and malignant melanoma
Boyle, G. M., Martyn, A. C., & Parsons, P. G. (2005) · Pigment Cell Research · doi:10.1111/j.1600-0749.2005.00228.x · Cited by 72
Uciechowska, U., Schemies, J., Neugebauer, R. C., Huda, E., Schmitt, M., Meier, R., Verdin, E. M., Jung, M., & Sippl, W. (2008) · ChemMedChem · doi:10.1002/cmdc.200800104 · Cited by 64
Yao, Y., Tu, Z., Liao, C., Wang, Z., Li, S., Yao, H., Li, Z., & Jiang, S. (2015) · Journal of Medicinal Chemistry · doi:10.1021/acs.jmedchem.5b01044 · Cited by 65
SelSA, selenium analogs of SAHA as potent histone deacetylase inhibitors
Desai, D. H., Salli, U., Vrana, K. E., & Amin, S. (2009) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2009.07.068 · Cited by 68
Chemistry and biology of mercaptoacetamides as novel histone deacetylase inhibitors
Chen, B., Petukhov, P. A., Jung, M., Velena, A., Eliseeva, E. D., Dritschilo, A., & Kozikowski, A. P. (2005) · Bioorganic & Medicinal Chemistry Letters · doi:10.1016/j.bmcl.2005.01.006 · Cited by 67
Modulation of angiogenesis-related protein synthesis by valproic acid
Zgouras, D., Becker, U., Loitsch, S. M., & Stein, J. M. (2004) · Biochemical and Biophysical Research Communications · doi:10.1016/j.bbrc.2004.02.105 · Cited by 75
Igotti, M. V., Pospelova, T. V., Nikulenkov, F., Hollander, C. M., Fornace, A. J., & Pospelov, V. A. (2006) · Journal of Biological Chemistry · doi:10.1074/jbc.m511059200 · Cited by 75
Sirtuins (histone deacetylases III) in the cellular response to DNA damage—Facts and hypotheses
Kruszewski, M. K., & Szumiel, I. (2005) · DNA repair · doi:10.1016/j.dnarep.2005.06.013 · Cited by 75
“[14] R.”
BackgroundChoi, Y., Park, S., Kim, H. M., Kang, J. S., Yoon, Y. D., Han, S., Han, J. W., Yang, J. S., & Han, G. (2008) · Experimental & Molecular Medicine · doi:10.3858/emm.2008.40.5.574 · Cited by 63
Transcriptional Regulation of Endothelial Arginase 2 by Histone Deacetylase 2
Pandey, D., Sikka, G., Bergman, Y., Kim, J. H., Ryoo, S., Romer, L., & Berkowitz, D. (2014) · Arteriosclerosis, Thrombosis, and Vascular Biology · doi:10.1161/atvbaha.114.303685 · Cited by 64
Davies, E. R., Haitchi, H. M., Thatcher, T. H., Sime, P. J., Kottmann, R. M., Ganesan, A., Packham, G. K., O’Reilly, K. M., & Davies, D. E. (2012) · American Journal of Respiratory Cell and Molecular Biology · doi:10.1165/rcmb.2011-0040oc · Cited by 65
“Imbalances in HAT/HDAC activity have been associated with several diseases, most notably the dysregulation of cell-cycle control linked to uncontrolled proliferation in several cancers (14, 15).”
BackgroundFrom Bench to Bedside: Lessons Learned in Translating Preclinical Studies in Cancer Drug Development
Lieu, C. H., Tan, A.-C., Leong, S., Diamond, J. R., & Eckhardt, S. G. (2013) · JNCI Journal of the National Cancer Institute · doi:10.1093/jnci/djt209 · Cited by 61
HDAC9 Inhibits Osteoclastogenesis via Mutual Suppression of PPARγ/RANKL Signaling
Jin, Z., Wei, W., Huynh, H., & Wan, Y. (2015) · Molecular Endocrinology · doi:10.1210/me.2014-1365 · Cited by 69
Gong, Y., Himmerkus, N., Plain, A., Bleich, M., & Hou, J. (2014) · Journal of the American Society of Nephrology · doi:10.1681/asn.2014020129 · Cited by 65
Targeting cancer using KAT inhibitors to mimic lethal knockouts
Brown, J. A. L., Bourke, E., Eriksson, L. A., & Kerin, M. J. (2016) · Biochemical Society Transactions · doi:10.1042/bst20160081 · Cited by 64
Zhang, L., Freitas, M. A., Wickham, J., Parthun, M. R., Klisovic, M. I., Marcucci, G., & Byrd, J. C. (2003) · Journal of the American Society for Mass Spectrometry · doi:10.1016/j.jasms.2003.10.001 · Cited by 73
“Compounds that manipulate histone post-translational modification by inhibiting histone deacetylases have shown promise as potential cancer therapeutics in a variety of preclinical studies [21–28].”
BackgroundCheng, Y., Yang, M., & Matter, A. M. (2007) · Applied and Environmental Microbiology · doi:10.1128/aem.01751-06 · Cited by 72
“Histone acetylation catalyzed by histone acetyltransferases is an important component of chromatin remodeling and gene expression regulation; histone hypoacetylation mediated by HDACs is often associated with the onset and progression of cancer (24, 57).”
BackgroundZardo, G., Cimino, G. G., & Nervi, C. (2008) · Leukemia · doi:10.1038/leu.2008.141 · Cited by 75
García-Morales, P., Gómez‐Martínez, Á., Carrato, A., Martínez-Lacaci, I., Barberá, V. M., Soto, J. L., Carrasco‐García, E., Menéndez-Gutierrez, M. P., Castro-Galache, M. D., Ferragut, J. A., et al. (2005) · Molecular Cancer Therapeutics · doi:10.1158/1535-7163.mct-04-0186 · Cited by 63
“to increase the expression of FAS and FAS ligand in other systems (21, 23, 42).”
BackgroundNew Insights Into the Epigenetic Regulation of Inflammatory Bowel Disease
Xu, J., Xu, H., Yang, M., Liang, Y.-J., Peng, Q., Zhang, Y., Tian, C., Wang, L., Yao, J., Nie, Y., et al. (2022) · Frontiers in Pharmacology · doi:10.3389/fphar.2022.813659 · Cited by 71
“There are various types of histone modification, and 12 types have been identified at present (Johnstone, 2002), including acetylation, methylation, ubiquitination, phosphorylation, glycosylation, or citrullination (Figure 2).”
BackgroundIbhazehiebo, K., Gavrilovici, C., de la Hoz, C. L. R., Ma, S., Rehak, R., Kaushik, G., Santoscoy, P. L. M., Scott, L. O. M., Nath, N. N., Kim, D. Y., et al. (2018) · Brain · doi:10.1093/brain/awx364 · Cited by 69
“HDACs control various cellular functions by altering the dynamics of chromatin structure, which thereby affects gene transcription and can contribute to the pathogenesis of various diseases (Johnstone, 2002).”
BackgroundShort-Chain Fatty Acids in the Metabolism of Heart Failure – Rethinking the Fat Stigma
Palm, C. L., Nijholt, K. T., Bakker, B. M., & Westenbrink, B. D. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.915102 · Cited by 65
“In addition to serving as a fuel, SCFAs inhibit histone deacetylases (HDACs) which are known to promote inflammation and tumourigenesis (46, 47).”
BackgroundGao, Y., Duan, J., Dang, X., Yuan, Y., Wang, Y., He, X., Bai, R., Ye, X., & Xie, T. (2023) · Journal of Enzyme Inhibition and Medicinal Chemistry · doi:10.1080/14756366.2023.2195991 · Cited by 66
Targeted therapies for advanced non-small-cell lung cancer: Current status and future implications
Custodio, A., Méndez, M., & Provencio, M. (2011) · Cancer Treatment Reviews · doi:10.1016/j.ctrv.2011.04.001 · Cited by 65
Identification of ligand features essential for HDACs inhibitors by pharmacophore modeling
Chen, Y., Jiang, Y., Zhou, J., Yu, Q., & You, Q. (2007) · Journal of Molecular Graphics and Modelling · doi:10.1016/j.jmgm.2007.10.007 · Cited by 61
Narita, K., Kikuchi, T., Watanabe, K., Takizawa, T., Oguchi, T., Kudo, K., 松原圭介, Abe, H., Yamori, T., Yoshida, M., et al. (2009) · Chemistry - A European Journal · doi:10.1002/chem.200901552 · Cited by 65
Lee, H., Kim, Y. J., Kim, H. W., Lee, D. H., Sung, M., & Park, T. (2006) · Biological and Pharmaceutical Bulletin · doi:10.1248/bpb.29.670 · Cited by 61
Mukhopadhyay, N. K., Weisberg, E., Gilchrist, D., Bueno, R., Sugarbaker, D. J., & Jaklitsch, M. T. (2006) · The Annals of Thoracic Surgery · doi:10.1016/j.athoracsur.2005.06.059 · Cited by 68
Nawrocki, S. T., Carew, J. S., Douglas, L., Cleveland, J. L., Humphreys, R. C., & Houghton, J. A. (2007) · Cancer Research · doi:10.1158/0008-5472.can-07-0812 · Cited by 62
“inhibitor p21(23), which is also a transcription target induced by the”
BackgroundPharmocoepigenetics: a new approach to predicting individual drug responses and targeting new drugs
Baer‐Dubowska, W., Majchrzak‐Celińska, A., & Cichocki, M. (2011) · Pharmacological Reports · doi:10.1016/s1734-1140(11)70498-4 · Cited by 65
“The HDACs inhibitors include small-chain fatty acids, hydroxamic acids, cyclic tetrapeptides, benzamides and other compounds that do not fit in these classifications, such as electrophilic ketones [37, 56].”
BackgroundOkamura, Y., Nomoto, S., Kanda, M., Hayashi, M., Nishikawa, Y., Fujii, T., Sugimoto, H., Takeda, S., & Nakao, A. (2010) · Annals of Surgical Oncology · doi:10.1245/s10434-010-1273-z · Cited by 64
“A new pharmacological approach used in cancer therapy consists of the use of histone deacetylase (HDAC) inhibitors to elicit histone hyperacetylation.(23) Valproic acid is an HDAC inhibitor that is administered orally; it is relatively safe and has been used to treat epilepsy and bipolar disorder for many decades.”
MethodYao, Y., Liao, C., Li, Z., Wang, Z., Sun, Q., Liu, C., Yang, Y., Tu, Z., & Jiang, S. (2014) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2014.09.024 · Cited by 61
“The isoform assays showed that all 5 compounds displayed good selectivity on class I HDAC isoforms (HDAC1, 2, 3 and 8) and class IIb HDAC isoforms (HDAC6 and 10) over class IIA HDACs (HDAC4, 5, 7 and 9), and class IV HDAC11.”
BackgroundMühlethaler‐Mottet, A., Meier, R., Flahaut, M., Bourloud, K. B., Nardou, K., Joseph, J., & Groß, N. (2008) · Molecular Cancer · doi:10.1186/1476-4598-7-55 · Cited by 60
“For example, cell cycle arrest was described to occur in G1/ S or in G2/M depending on the tumour cell types studied [5,10,11].”
BackgroundRevisiting Histone Deacetylases in Human Tumorigenesis: The Paradigm of Urothelial Bladder Cancer
Giannopoulou, A. F., Velentzas, A. D., Konstantakou, E. G., Avgeris, M., Katarachia, S. A., Papandreou, N. C., Kalavros, N., Mpakou, V., Iconomidou, V. A., Anastasiadou, E., et al. (2019) · International Journal of Molecular Sciences · doi:10.3390/ijms20061291 · Cited by 65
Mai, A., Massa, S., Pezzi, R., Rotili, D., Loidl, P., & Brosch, G. (2003) · Journal of Medicinal Chemistry · doi:10.1021/jm034167p · Cited by 59
Wang, J., Mahmud, S. A., Bitterman, P. B., Huo, Y., & Slungaard, A. (2007) · Journal of Biological Chemistry · doi:10.1074/jbc.m703586200 · Cited by 65
Mai, A., Massa, S., Cerbara, I., Valente, S., Ragno, R., Bottoni, P., Scatena, R., Loidl, P., & Brosch, G. (2004) · Journal of Medicinal Chemistry · doi:10.1021/jm030990+ · Cited by 67
Egler, V., Korur, S., Failly, M., Boulay, J., Imber, R., Lino, M. M., & Merlo, A. (2008) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-07-4182 · Cited by 64
Yildirim, E., Zhang, Z., Uz, T., Chen, C., Manev, R. M., & Manev, H. (2003) · Neuroscience Letters · doi:10.1016/s0304-3940(03)00490-7 · Cited by 64
The histone deacetylase inhibitor, romidepsin, as a potential treatment for pulmonary fibrosis
Conforti, F., Davies, E. R., Calderwood, C., Thatcher, T. H., Jones, M. G., Smart, D. E., Mahajan, S., Alzetani, A., Havelock, T., Maher, T. M., et al. (2017) · Oncotarget · doi:10.18632/oncotarget.17114 · Cited by 62
“Several studies, including one in IPF fibroblasts, have suggested that suppression of proliferation by HDAC inhibitors is due to induction of cell cycle arrest involving up-regulation of cell-cycle inhibitors such as CDKN1A (p21waf1) [17, 35, 36].”
BackgroundAbaza, Y. M., Kadia, T. M., Jabbour, E. J., Konopleva, M. Y., Borthakur, G., Ferrajoli, A., Estrov, Z., Wierda, W. G., Alfonso, A., Chong, T. H., et al. (2017) · Cancer · doi:10.1002/cncr.30949 · Cited by 58
“HDAC inhibitors (HDACIs) can reactivate gene expression and promote cell-cycle arrest, differentiation, and apoptosis through the induction of histone acetylation resulting in chromatin relaxation increasing the accessibility of transcription factors to their target genes.(1,5,8,9) Pracinostat, 3-(2-butyl-1-(2-diethyl…”
BackgroundGut Microbiota of Wild and Captive Alpine Musk Deer (Moschus chrysogaster)
Sun, Y., Sun, Y., Shi, Z., Liu, Z., Zhao, C. S., Lu, T., Gao, H., Zhu, F., Chen, R., Zhang, J., et al. (2020) · Frontiers in Microbiology · doi:10.3389/fmicb.2019.03156 · Cited by 67
“Butyrate and propionate can protect against colorectal cancer and inflammation, at least partly by inhibiting histone deacetylases HDACs (Johnstone, 2002; Flint et al., 2012).”
BackgroundCooper, A. L., Greenberg, V. L., Lancaster, P. S., van Nagell, J. R., Zimmer, S. G., & Modesitt, S. C. (2006) · Gynecologic Oncology · doi:10.1016/j.ygyno.2006.09.011 · Cited by 65
VanOosten, R. L., Moore, J. M., Karaçay, B., & Griffith, T. S. (2005) · Cancer Biology & Therapy · doi:10.4161/cbt.4.10.2022 · Cited by 63
“Depsipeptide [(E)-(1S,4S,10S,21R)-7-[(Z) -ethylidene]-4,21-diisopropyl-2-oxa-12,13-dithia-5,8,20,23-tetraazabicyclo -[8,7,6]-tricos-16-ene-3,6,9,19,22-pentanone; FR901228, FK228] was obtained from the Drug Synthesis & Chemistry Branch, Developmental Therapeutics Program, Division of Cancer Treatment and Diagnosis, Nat…”
MethodBeneden, K. V., Geers, C., Pauwels, M., Mannaerts, I., Wissing, K. M., Branden, C. V. D., & van Grunsven, L. A. (2013) · Toxicology and Applied Pharmacology · doi:10.1016/j.taap.2013.05.013 · Cited by 68
“HDAC inhibitors have been extensively studied in experimental models of cancer, where their inhibition of deacetylation has been proven to regulate cell survival, proliferation, differentiation and apoptosis (Johnstone, 2002; Marks and Xu, 2009).”
BackgroundRundall, B. K., Denlinger, C. E., & Jones, D. R. (2004) · Surgery · doi:10.1016/j.surg.2004.05.018 · Cited by 68
Histone deacetylase inhibitors differentially mediate apoptosis in prostate cancer cells
Frønsdal, K. B., & Saatcioglu, F. (2004) · The Prostate · doi:10.1002/pros.20140 · Cited by 67
“HDAC inhibitors are therefore potential anticancer agents, both chemopreventive and chemotherapeutic, and are currently being evaluated in clinical trials on solid tumors, including prostate cancer [17,18].”
Synthesis and Biological Validation of Novel Synthetic Histone/Protein Methyltransferase Inhibitors
Mai, A., Valente, S., Cheng, D., Perrone, A., Ragno, R., Simeoni, S., Sbardella, G., Brosch, G., Nebbioso, A., Conte, M., et al. (2007) · ChemMedChem · doi:10.1002/cmdc.200700023 · Cited by 64
Floris, G., Dêbiec‐Rychter, M., Sciot, R., Stefan, C., Fieuws, S., Machiels, K., Atadja, P. W., Woźniak, A., Faa, G., & Schöffski, P. (2009) · Clinical Cancer Research · doi:10.1158/1078-0432.ccr-08-2588 · Cited by 63
“This finding is in line with the hypothesis that histone hyperacetylation of the pericentromeric heterochromatin occurring in the presence of HDACi leads to abnormal chromosomal segregation, nuclear fragmentation, and cell death due to aberrant mitosis (11).”
BackgroundResultInfluentialLee, K. J., Lee, K. Y., & Lee, Y. M. (2010) · Biochimica et Biophysica Acta (BBA) - Molecular Cell Research · doi:10.1016/j.bbamcr.2010.01.004 · Cited by 64
Baradari, V., Höpfner, M., Huether, A., Schuppan, D., & Scherübl, H. (2007) · World Journal of Gastroenterology · doi:10.3748/wjg.v13.i33.4458 · Cited by 58
“HDAC inhibitor monotherapy can inhibit the growth of various tumors in vitro and in vivo [11,15, 17 ]”
BackgroundSynthesis and Biological Properties of Novel, Uracil-Containing Histone Deacetylase Inhibitors
Mai, A., Massa, S., Rotili, D., Simeoni, S., Ragno, R., Botta, G., Nebbioso, A., Miceli, M., Altucci, L., & Brosch, G. (2006) · Journal of Medicinal Chemistry · doi:10.1021/jm0605536 · Cited by 60
Mechanism of histone deacetylases in cardiac hypertrophy and its therapeutic inhibitors
Han, Y., Nie, J., Wang, D. W., & Li, N. (2022) · Frontiers in Cardiovascular Medicine · doi:10.3389/fcvm.2022.931475 · Cited by 66
Targeting Epigenetic Mechanisms: Potential of Natural Products in Cancer Chemoprevention
Hauser, A., & Jung, M. (2008) · Planta Medica · doi:10.1055/s-2008-1081347 · Cited by 62
“The HDAC inhibitors are classified into different groups depending on their structure, including (a) small-chain fatty acids, (b) hydroxamic acids, (c) cyclic tetrapep-tides, (d) benzamides and others that do not fit in these classifications [70], [71].”
InfluentialCatalano, M. G., Pugliese, M., Gargantini, E., Grange, C., Bussolati, B., Asioli, S., Bosco, O., Poli, R., Compagnone, A., Bandino, A., et al. (2011) · International Journal of Cancer · doi:10.1002/ijc.26057 · Cited by 58
“This behavior is in agreement with previous observations showing that DCI usually determine cytotoxicity at higher doses and induce G1 arrest at lower doses.(28,29)”
ResultGolfier, S., Rosendahl, P., Mietke, A., Herbig, M., Guck, J. R., & Otto, O. (2017) · Cytoskeleton · doi:10.1002/cm.21369 · Cited by 62
“The ensuing structural transition of the chromatin was found to take place for submicro-molar concentrations of TSA (Johnstone, 2002) and resulted in reduced nuclear rigidity (Chalut et al.”
BackgroundPharmacologic and Chemical Adjuvants in Tumor Virotherapy
Alvarez-Breckenridge, C. A., Kaur, B., & Chiocca, E. A. (2009) · Chemical Reviews · doi:10.1021/cr900048k · Cited by 62
Histone Deacetylation as a Target for Radiosensitization
Cerna, D., Camphausen, K. A., & Tofilon, P. J. (2006) · Current topics in developmental biology/Current Topics in Developmental Biology · doi:10.1016/s0070-2153(05)73006-4 · Cited by 59
Upregulation of ABCG2 by Romidepsin via the Aryl Hydrocarbon Receptor Pathway
To, K. K. W., Robey, R. W., Zhan, Z., Bangiolo, L., & Bates, S. E. (2011) · Molecular Cancer Research · doi:10.1158/1541-7786.mcr-10-0270 · Cited by 59
“Although differential display (44) or microarray analyses (45) identified only 2% to 10% of expressed genes as sensitive to HDACIs, we have found a gene responding toHDAC inhibition in some cell lines but not in others.”
BackgroundNovel isatin-based hydroxamic acids as histone deacetylase inhibitors and antitumor agents
Nam, N., Huong, T. L., Dung, D. T. M., Dung, P. T. P., Oanh, D. T. K., Quyen, D., Thảo, L. T. P., Park, S. H., Kim, K. R., Han, B. W., et al. (2013) · European Journal of Medicinal Chemistry · doi:10.1016/j.ejmech.2013.10.045 · Cited by 58
Epigenetic silencing of the WNT antagonist DICKKOPF-1 in cervical cancer cell lines
Lee, J., Yoon, Y. S., & Chung, J. H. (2008) · Gynecologic Oncology · doi:10.1016/j.ygyno.2008.01.034 · Cited by 56
“Histone deacetylation is the major epigenetic silencing mechanism of some tumor suppressor genes in addition to promoter hypermethylation [15].”
Background
Metadata
- Authors
- Johnstone, R. W.
- Affiliations
- Peter MacCallum Cancer Centre (AU)
- Corresponding author
- Johnstone, Ricky W.
- ORCID
- Johnstone, Ricky W.
- Venue
- Nature Reviews Drug Discovery
- Published
- 2002-04
- Volume
- 1
- Issue
- 4
- Pages
- 287-299
- ISSN
- 1474-1776 (ISSN-L)
- 1474-1784
- OpenAlex
- W1971621147
- Cited by
- 1,515
- References
- 121
- Citations by year
- 2026: 9 · 2025: 21 · 2024: 23 · 2023: 46 · 2022: 35 · 2021: 59 · 2020: 50 · 2019: 55 · 2018: 38 · 2017: 65 · 2016: 50 · 2015: 64 · 2014: 54 · 2013: 81 · 2012: 94
- FWCI
- 5.84
- Type
- journal article
- Language
- en
- Open access
- closed
- Licence
- www.springer.com/tdm (tdm)
- Locations
- Nature Reviews Drug Discovery (publishedVersion)
- PubMed (publishedVersion)
- Funders
- Wellcome Trust
- National Health and Medical Research Council
- National Medical Research Council
- Topics
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Histone Deacetylase Inhibitors Research
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Epigenetics and DNA Methylation
- Life Sciences › Biochemistry, Genetics and Molecular Biology › Molecular Biology › Genomics and Chromatin Dynamics
- Keywords
- histone deacetylase inhibitors, histone acetyltransferase, chromatin remodeling, gene expression regulation, aberrant transcription, tumor cell growth inhibition, cancer therapy
- MeSH terms
- Acetylation, Animals, Antineoplastic Agents, Cell Differentiation, Chromatin, Clinical Trials as Topic, Enzyme Inhibitors, Histones, Humans, Neoplasms, Gene Expression Regulation, Neoplastic, Apoptosis, DNA Methylation, Histone Deacetylase Inhibitors
About these checks
Registry, retraction, Cites and statistics results are computed, not judged, with one exception: a printed reference that no index lists is read once by a model before it counts as a citation error. Claims are extracted by a model and kept only when their quote appears verbatim in the text; each cited source is then checked, with a model’s help, for whether it says what the claim relies on. Those verdicts can be wrong — read the claim’s quote and the cited source before relying on one.
Statistics and arithmetic are recomputed, not judged.
Confidence bands are shown only for fields calibrated on our annotated test set. None is calibrated yet, so no band is shown.
What counts as a claim ›How we measure confidence ›How we check this ›
Are you an author, or do you see a problem with this page? Request a review
Data sources
Bibliographic data: Semantic Scholar, OpenAlex, Crossref.
Contains information from the Semantic Scholar Academic Graph Datasets, made available under the ODC Attribution License (ODC-BY 1.0).
Semantic Scholar’s data is described in: Kinney, R., et al. (2023). The Semantic Scholar Open Data Platform. arXiv:2301.10140.